These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25654695)

  • 1. Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs.
    Roopenian DC; Low BE; Christianson GJ; Proetzel G; Sproule TJ; Wiles MV
    MAbs; 2015; 7(2):344-51. PubMed ID: 25654695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs.
    Viuff D; Antunes F; Evans L; Cameron J; Dyrnesli H; Thue Ravn B; Stougaard M; Thiam K; Andersen B; Kjærulff S; Howard KA
    J Control Release; 2016 Feb; 223():22-30. PubMed ID: 26699424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human
    Low BE; Christianson GJ; Lowell E; Qin W; Wiles MV
    MAbs; 2020; 12(1):1829334. PubMed ID: 33025844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Humanized Mouse Model to Study Human Albumin and Albumin Conjugates Pharmacokinetics.
    Low BE; Wiles MV
    Methods Mol Biol; 2016; 1438():115-22. PubMed ID: 27150087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
    Proetzel G; Roopenian DC
    Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities.
    Tam SH; McCarthy SG; Brosnan K; Goldberg KM; Scallon BJ
    MAbs; 2013; 5(3):397-405. PubMed ID: 23549129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
    Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
    Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.
    Fan YY; Avery LB; Wang M; O'Hara DM; Leung S; Neubert H
    MAbs; 2016 Jul; 8(5):848-53. PubMed ID: 27104806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
    Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
    J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative Analysis of Human Neonatal Fc Receptor (FcRn) Tissue Expression in Transgenic Mice by Online Peptide Immuno-Affinity LC-HRMS.
    Fan YY; Neubert H
    Anal Chem; 2016 Apr; 88(8):4239-47. PubMed ID: 27012525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.
    Avery LB; Wang M; Kavosi MS; Joyce A; Kurz JC; Fan YY; Dowty ME; Zhang M; Zhang Y; Cheng A; Hua F; Jones HM; Neubert H; Polzer RJ; O'Hara DM
    MAbs; 2016; 8(6):1064-78. PubMed ID: 27232760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies of the serum half-life extension of a protein via site-specific conjugation to a species-matched or -mismatched albumin.
    Yang B; Kim JC; Seong J; Tae G; Kwon I
    Biomater Sci; 2018 Jul; 6(8):2092-2100. PubMed ID: 29881837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn).
    Sand KM; Bern M; Nilsen J; Dalhus B; Gunnarsen KS; Cameron J; Grevys A; Bunting K; Sandlie I; Andersen JT
    J Biol Chem; 2014 Dec; 289(50):34583-94. PubMed ID: 25344603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A precisely humanized FCRN transgenic mouse for preclinical pharmacokinetics studies.
    Conner CM; van Fossan D; Read K; Cowley DO; Alvarez O; Xu SX; Webb DR; Jarnagin K
    Biochem Pharmacol; 2023 Apr; 210():115470. PubMed ID: 36870576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling.
    Merten H; Brandl F; Zimmermann M; Schaefer JV; Irpinio L; Sand KMK; Nilsen J; Andersen JT; Zangemeister-Wittke U; Plückthun A
    Eur J Pharm Biopharm; 2021 Oct; 167():104-113. PubMed ID: 34303832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
    Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
    MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FcRn binding properties of an abnormal truncated analbuminemic albumin variant.
    Andersen JT; Daba MB; Sandlie I
    Clin Biochem; 2010 Mar; 43(4-5):367-72. PubMed ID: 20006594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice.
    Kliwinski C; Cooper PR; Perkinson R; Mabus JR; Tam SH; Wilkinson TM; Giles-Komar J; Scallon B; Powers GD; Hornby PJ
    Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(3):G262-70. PubMed ID: 23220220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life.
    Adams R; Griffin L; Compson JE; Jairaj M; Baker T; Ceska T; West S; Zaccheo O; Davé E; Lawson AD; Humphreys DP; Heywood S
    MAbs; 2016 Oct; 8(7):1336-1346. PubMed ID: 27315033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface.
    Schmidt MM; Townson SA; Andreucci AJ; King BM; Schirmer EB; Murillo AJ; Dombrowski C; Tisdale AW; Lowden PA; Masci AL; Kovalchin JT; Erbe DV; Wittrup KD; Furfine ES; Barnes TM
    Structure; 2013 Nov; 21(11):1966-78. PubMed ID: 24120761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.